Sanofi’s Xenpozyme approved by European Commission

Xenpozyme is a treatment for ASMD and the condition’s only current enzyme replacement therapy

Read on PharmaTimes

Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor

Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain

Read on PharmaTimes

Sirana enters into collaborative research agreement with Pfizer

Companies will combine to investigate a novel treatment for a rare bone disease

Read on PharmaTimes

Atos opens Life Science Centre of Excellence

Centre will accelerate drug development and enable precision health solutions

Read on PharmaTimes

First treatment for ‘broken heart syndrome’ trialled

Scientists will trial a programme of exercise conditioning and psychological therapy for people diagnosed with the condition

Read on PharmaTimes

1 2 3

Top of page

Industry News

Xenpozyme is a treatment for ASMD and the condition’s only current enzyme replacement therapy.
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us